At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium, discusses a phase 1b clinical trial that was designed to evaluate the safety and antitumour activity of durvalumab, an anti-PD-L1 antibody, combined with tremelimumab, a CTLA-4 antibody, for the treatment of patients with stage III or IV non-small cell lung cancer.
Phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer
5th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now